September 2014 – Unraveling Treatment
Table of Contents
Therapies with Reduced Toxicity for the Treatment of CLL and APL — An Update on Currently Available and Up-and-Coming Options
NE Oncology Issue - September 2014 Leukemias In the treatment of many cancers, a common concern is the development of a therapeutic regimen that will achieve high efficacy with minimal toxicities. In chronic lymphocytic leukemia (CLL), the...
Severe infections are more common in physically fit CLL patients with FCR-therapy compared to bendamustine plus rituximab
NE Oncology Issue - September 2014 Langerbeins P et al. EHA 2014:P237 Background Infections are a common complication in patients with CLL who are receiving chemoimmunotherapy, which greatly impacts the course of disease. The combination...
Efficacy and safety of bendamustine in combination with rituximab for elderly patients with previously untreated B-cell CLL — an Italian, retrospective, multicentre study
NE Oncology Issue - September 2014 Laurenti L et al. EHA 2014:P875 Background Chemoimmunotherapy with fludarabine, cyclophosphamide, and rituximab (FCR) is the front-line therapy for young patients with chronic lymphocytic leukemia (CLL),...
Bendamustine in combination with rituximab as first-line therapy for patients with CLL — real-world clinical practice reviewed in an Italian, retrospective, multicentre study
NE Oncology Issue - September 2014 Gentile M et al. EHA 2014:PB1503 Background In recent clinical studies, the combination of bendamustine plus rituximab (BR) has produced promising results in the treatment of relapsed/refractory and...
Bendamustine-based first-line therapy in CLL in routine clinical practice — interim analysis of the German non-interventional study Be-CeLL1st
NE Oncology Issue - September 2014 Bruch H-R et al. EHA 2014:PB1504 Background Bendamustine is an established treatment option for chronic lymphocytic leukemia (CLL) and is frequently used in daily practice in Germany. Be-CeLL1st is a...
NE Oncology Issue - September 2014 Gozzetti A et al. EHA 2014:PB1529 Background A combination of fludarabine, cyclophosphamide, and rituximab (FCR) is the current standard therapy for young, fit patients with chronic lymphocytic leukemia...
Salvage treatment with bendamustine, ofatumumab, and high-dose methylprednisolone (BOMP) in high-risk relapsed/refractory CLL — interim results of the ICLL01 phase II trial
NE Oncology Issue - September 2014 de Guibert S et al. EHA 2014:P247 Background A number of agents have produced promising results in the treatment of poor prognosis patients with relapsed or refractory chronic lymphocytic leukemia (R/R...
NE Oncology Issue - September 2014 Coutre S et al. EHA 2014:S704 Background The oral inhibitor of PI3Kδ, idelalisib, is highly active in heavily pretreated patients with chronic lymphocytic leukemia (CLL), either as a single agent or in...
Efficacy of idelalisib in CLL subpopulations harbouring del(17p) and other adverse prognostic factors
NE Oncology Issue - September 2014 Stilgenbauer S et al. EHA 2014:S1341 Background An unmet need exists for effective therapies in patients with chronic lymphocytic leukemia (CLL) positive for del(17p) and other adverse prognostic factors....
Pre-treatment with idelalisib markedly reduces rituximab infusion-related reactions and infusion interruptions in patients with CLL
NE Oncology Issue - September 2014 Hillmen P et al. EHA 2014: P236 Background Infusion related reactions (IRRs) during the first infusion of rituximab in patients with chronic lymphocytic leukemia (CLL) have been reported to occur...
Carolyn Owen, MD
Dr. Carolyn Owen completed postgraduate training in internal medicine and hematology at the University of Ottawa and the University of British Columbia, respectively, followed by a research fellowship in molecular genetics at Barts and the London School of Medicine and Dentistry in London, UK. Her research focused on familial myelodysplasia and acute myeloid leukemia. She is currently an Assistant Professor at the Foothills Medical Centre & Tom Baker Cancer Centre, and her clinical interests are low-grade lymphoma and chronic lymphocytic leukemia. She is also the local principal investigator in Calgary for several clinical trials in these areas.
David Macdonald, MD, FRCPC
Dr. David Macdonald is a hematologist at the QEII Health Sciences Centre in Halifax, Nova Scotia, and Assistant Professor in the Division of Hematology at Dalhousie University’s Faculty of Medicine. Dr. Macdonald chairs the Hematology Cancer Site Team for Cancer Care Nova Scotia. His interests are in hematologic malignancies and, in particular, lymphoproliferative disorders. He has done a Clinical Trials Fellowship with the National Cancer Institute of Canada – Clinical Trials Groups and is actively engaged in clinical trials research. Dr. Macdonald has also completed a clinical fellowship in the lymphoma group at the British Columbia Cancer Agency in Vancouver, and he maintains a clinical research program in lymphoma.
Jeffrey Rothenstein, MD, FRCPC
Dr. Jeffrey Rothenstein is a medical oncologist at the R.S. McLaughlin Durham Regional Cancer Centre in Oshawa and an Adjunct Assistant Professor in the Department of Oncology at Queen’s University in Kingston, Ontario. He completed his internal medicine and medical oncology training at the University of Toronto. Dr. Rothenstein’s main clinical focus is on the management of thoracic and gastrointestinal malignancies. He is the lung cancer site group leader at the R.S. McLaughlin Durham Regional Cancer Center.
Stephan Stilgenbauer, MD
Dr. Stephan Stilgenbauer is Associate Professor and Deputy Chairman at the Department of Internal Medicine III (Hematology, Oncology, Rheumatology and Infectious Diseases) at Ulm University, Germany. He received his medical training at Heidelberg Medical School and was trained in internal medicine and hematology-oncology at the Universities of Heidelberg and Ulm. He spent a postdoctoral fellowship at the German Cancer Research Center (DKFZ) in Heidelberg. His research focus is on the molecular pathogenesis of hematological malignancies and translation of this research into novel treatment strategies. Dr. Stilgenbauer has authored or co-authored numerous original articles, reviews, and book chapters in journals such as The New England Journal of Medicine, The Lancet, Nature Medicine, the Proceedings of the National Academy of Sciences of the United States of America, Journal of Clinical Oncology, Blood, Leukemia, Haematologica, among others.
C. Tom Kouroukis, MD
Dr. C. Tom Kouroukis graduated from the University of Toronto and completed training in Internal Medicine, Hematology and MSc (Health Research Methodology) training at McGill and McMaster Universities. He was awarded a National Cancer Institute of Canada Clinical Research Fellowship. He is a hematologist at the Juravinski Cancer Centre/Hamilton Health Science, Chair of the Hematology Disease Site Team, Head of the Division of Malignant Hematology, and Associate Professor in the Department of Oncology. He is Co-chair of the Hematology Cancer Disease Site Group of the Cancer Care Ontario Practice Guidelines Initiative and Chair of the Stem Cell Committee of Cancer Care Ontario. His research interests include the care of older patients with hematological cancers, the impact and evaluation of co-morbidity in older cancer patients, clinical trials, and practice guideline development.
Laurie H. Sehn, MD, MPH
Dr. Laurie H. Sehn is a Clinical Assistant Professor at the BC Cancer Agency and the University of British Columbia in Vancouver. She has been a medical oncologist and clinical investigator with the Lymphoma Tumour Group since 1998. Dr. Sehn has served on the Board of Directors of Lymphoma Foundation Canada (LFC) since 2002 and is currently Director of Research Fellowships for the LFC. Dr. Sehn’s research interests include all of the lymphoid cancers, with particular interest in the biology and treatment of large-cell lymphoma, the application of new imaging techniques such as PET scanning to lymphoma management, and innovative new approaches to treatment.
Dietger Niederwieser, MD
Dr. Dietger Niederwieser is the Head of the Department of Hematology and Oncology at the University Hospital of Leipzig in Germany. He completed his medical degree and postgraduate training in internal medicine and hemato-oncology at the University of Innsbruck in Austria. His research interests include leukemia, myelodysplastic syndrome, renal cell carcinoma, Hodgkin lymphoma, allogeneic stem cell transplantation, and graft versus host disease and he is currently involved in a variety of clinical trials in these areas. Dr. Niederwieser is President of the Worldwide Network for Blood and Marrow Transplantation, past President of the European Group for Bone and Marrow Transplantation (EBMT), and a former Chair of the EBMT Chronic Leukemia Working Party. He is a member of several scientific societies, including the European Hematology Association, the American Society of Hematology, and the American Society of Clinical Oncology and he serves as an external reviewer for universities in Europe and the United States. Dr. Niederwieser is the author or co-author of numerous articles (<390) published in international peer-reviewed journals, such as The New England Journal of Medicine, Blood, the Journal of Clinical Oncology, the Journal of the American Medical Association, Nature Clinical Practice Oncology, Annals of Oncology, Leukemia, and Bone Marrow Transplantation.
Barbara Melosky, MD, FRCP(C)
Dr. Barbara Melosky is a Clinical Associate Professor of Medicine at the University of British Columbia and a medical oncologist at the British Columbia Cancer Agency in Vancouver. She graduated from medical school at the University of Manitoba, and did a residency in internal medicine and an oncology fellowship at the University of British Columbia. Dr. Melosky is currently working in the fields of lung and gastrointestinal malignancies with a special interest in the side effects of targeted therapy. She sits on the Executive Committee for the Lung Disease Site NCIC Clinical Trials Group and is the annual Chair of the Canadian Lung Cancer Conference.